[
    [
        {
            "time": "2018-09-24",
            "original_text": "Animal health firm Elanco surges 41 percent on debut",
            "features": {
                "keywords": [
                    "Elanco",
                    "surges",
                    "debut"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "health",
                    "pharma"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Animal health firm Elanco surges 41 percent on debut",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 10,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-24",
            "original_text": "Eli Lilly Prices Animal Health Unit IPO at $24 Per Share",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "IPO",
                    "Animal Health",
                    "$24"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "health",
                    "pharma"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lilly Prices Animal Health Unit IPO at $24 Per Share",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-24",
            "original_text": "Elanco Animal Health stock soars more than 35% in trading debut",
            "features": {
                "keywords": [
                    "Elanco",
                    "soars",
                    "trading debut"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "health",
                    "pharma"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Elanco Animal Health stock soars more than 35% in trading debut",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 10,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-24",
            "original_text": "Elanco CEO on IPO, animal health focus",
            "features": {
                "keywords": [
                    "Elanco",
                    "CEO",
                    "IPO",
                    "animal health"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "health",
                    "pharma"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Elanco CEO on IPO, animal health focus",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-09-24",
            "original_text": "Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates",
            "features": {
                "keywords": [
                    "Pharma Stocks",
                    "GlaxoSmithKline",
                    "Revenue Trend",
                    "2018 Estimates"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharma"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-09-24",
            "original_text": "Pharma Stocks: Allergan’s Revenue Trend and 2018 Estimates",
            "features": {
                "keywords": [
                    "Pharma Stocks",
                    "Allergan",
                    "Revenue Trend",
                    "2018 Estimates"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharma"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Pharma Stocks: Allergan’s Revenue Trend and 2018 Estimates",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-09-24",
            "original_text": "Elanco’s $1.7 billion IPO looks too pricey, and here’s why",
            "features": {
                "keywords": [
                    "Elanco",
                    "IPO",
                    "$1.7 billion",
                    "pricey"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "health",
                    "pharma"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Elanco’s $1.7 billion IPO looks too pricey, and here’s why",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-24",
            "original_text": "Elanco’s $1.6 billion IPO looks too pricey, and here’s why",
            "features": {
                "keywords": [
                    "Elanco",
                    "IPO",
                    "$1.6 billion",
                    "pricey"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "health",
                    "pharma"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Elanco’s $1.6 billion IPO looks too pricey, and here’s why",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-24",
            "original_text": "D-Day Nearing For Antares Pharma",
            "features": {
                "keywords": [
                    "D-Day",
                    "Antares Pharma"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharma"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "D-Day Nearing For Antares Pharma",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]